Deep Track Capital Reports 6.17% Stake in Nurix Therapeutics, Inc. (NRIX)

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, reporting a 6.17% stake in Nurix Therapeutics, Inc. (NRIX). The reporting persons collectively hold 6,345,244 shares of common stock as of the event date of March 31, 2026. This filing represents an increase in holdings compared to the previous report where the ownership was listed at 0.0%. The shares are held with shared voting and dispositive power. David Kroin, as the Managing Member of the General Partner of the Investment Adviser and Director of the Master Fund, may be considered a control person for these entities. The filing is a passive investment declaration under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of influencing or changing the control of the issuer. The ownership percentage is based on 102,843,012 shares of common stock outstanding as of January 23, 2026.